{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:12:43Z","timestamp":1792177963014,"version":"4.4.0"},"reference-count":36,"publisher":"Microbiology Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9,1]]},"abstract":"<jats:p>Cross-neutralization between rabies virus (RABV) and two European bat lyssaviruses (EBLV-1 and -2) was analysed using lentiviral pseudotypes as antigen vectors. Glycoprotein (G-protein) cDNA from RABV challenge virus standard-11 (CVS-11) and EBLV-1 and -2 were cloned and co-expressed with human immunodeficiency virus (HIV) or murine leukemia virus (MLV) <jats:italic>gag<\/jats:italic>\u2013<jats:italic>pol<\/jats:italic> and packageable green fluorescent protein (GFP) or luciferase reporter genes in human cells. The harvested lentiviral (HIV) vector infected over 40\u200a% of baby hamster kidney (BHK) target cells, providing high-titre pseudotype stocks. Tests on blinded antibody-positive (<jats:italic>n<\/jats:italic>=15) and -negative (<jats:italic>n<\/jats:italic>=45) sera, predetermined by the fluorescent antibody virus neutralization (FAVN) test approved by the World Health Organization (WHO) and Office International des Epizooties (OIE), revealed that the CVS-11 pseudotype assay had 100\u200a% concordance with FAVN and strongly correlated with neutralization titres (<jats:italic>r<\/jats:italic>\n                  <jats:sup>2<\/jats:sup>=0.89). Cross-neutralization tests using sera from RABV-vaccinated humans and animals on pseudotypes with CVS-11, EBLV-1 and EBLV-2 envelopes showed that the relative neutralization titres correlated broadly with the degree of G-protein diversity. Pseudotypes have three major advantages over live-virus neutralization tests: (i) they can be handled in low-biohazard-level laboratories; (ii) the use of reporter genes such as GFP or <jats:italic>\u03b2<\/jats:italic>-galactosidase will allow the assay to be undertaken at low cost in laboratories worldwide; (iii) each assay requires &lt;10\u2005\u03bcl serum. This robust microassay will improve our understanding of the protective humoral immunity that current rabies vaccines confer against emerging lyssaviruses, and will be applicable to surveillance studies, thus helping to control the spread of rabies.<\/jats:p>","DOI":"10.1099\/vir.0.2008\/000349-0","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T15:45:58Z","timestamp":1219851958000},"page":"2204-2213","source":"Crossref","is-referenced-by-count":108,"title":["Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison"],"prefix":"10.1099","volume":"89","author":[{"given":"Edward","family":"Wright","sequence":"first","affiliation":[{"name":"MRC\/UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel J.","family":"Temperton","sequence":"additional","affiliation":[{"name":"MRC\/UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A.","family":"Marston","sequence":"additional","affiliation":[{"name":"Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency (Weybridge), WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine M.","family":"McElhinney","sequence":"additional","affiliation":[{"name":"Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency (Weybridge), WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Fooks","sequence":"additional","affiliation":[{"name":"Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency (Weybridge), WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin A.","family":"Weiss","sequence":"additional","affiliation":[{"name":"MRC\/UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.75.7.3268-3276.2001","article-title":"Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity","volume":"75","author":"Badrane","year":"2001","journal-title":"J Virol"},{"key":"R2","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet"},{"key":"R4","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.vaccine.2005.03.037","article-title":"Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses","volume":"23","author":"Brookes","year":"2005","journal-title":"Vaccine"},{"key":"R5","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1073\/pnas.81.9.2886","article-title":"Pseudotypes of human T-cell leukemia virus types 1 and 2: neutralization by patients' sera","volume":"81","author":"Clapham","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"Cliquet","year":"1998","journal-title":"J Immunol Methods"},{"key":"R7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jviromet.2003.12.001","article-title":"Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats","volume":"117","author":"Cliquet","year":"2004","journal-title":"J Virol Methods"},{"issue":"1","key":"R8","first-page":"19","article-title":"Principles of Virology. In Fields Virology","volume":"vol","author":"Condit","year":"2001"},{"key":"R9","first-page":"754","article-title":"Rabies virus glycoprotein","volume":"16","author":"Cox","year":"1977","journal-title":"II. Biological and serological characterization. Infect Immun"},{"key":"R10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1365-3083.2002.01015.x","article-title":"Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication","volume":"55","author":"Cox","year":"2002","journal-title":"Scand J Immunol"},{"key":"R11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/312763a0","article-title":"The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus","volume":"312","author":"Dalgleish","year":"1984","journal-title":"Nature"},{"key":"R12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/10430340252898984","article-title":"High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter","volume":"13","author":"Demaison","year":"2002","journal-title":"Hum Gene Ther"},{"key":"R13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/mthe.2001.0431","article-title":"Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins","volume":"4","author":"Desmaris","year":"2001","journal-title":"Mol Ther"},{"key":"R14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-1702(87)90023-2","article-title":"Localization and immunological characterization of antigenic domains of the rabies virus internal N and NS proteins","volume":"8","author":"Dietzschold","year":"1987","journal-title":"Virus Res"},{"key":"R15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/MCB.7.1.379","article-title":"Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system","volume":"7","author":"DuBridge","year":"1987","journal-title":"Mol Cell Biol"},{"key":"R16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14760584.3.4.333","article-title":"The challenge of new and emerging lyssaviruses","volume":"3","author":"Fooks","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"R17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2807\/esm.10.11.00574-en","article-title":"Rabies remains a \u2018neglected disease\u2019","volume":"10","author":"Fooks","year":"2005","journal-title":"Euro Surveill"},{"key":"R18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1017\/S0950268803001481","article-title":"European bat lyssaviruses: an emerging zoonosis","volume":"131","author":"Fooks","year":"2003","journal-title":"Epidemiol Infect"},{"key":"R19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2005.03.009","article-title":"Efficacy of rabies biologics against new lyssaviruses from Eurasia","volume":"111","author":"Hanlon","year":"2005","journal-title":"Virus Res"},{"key":"R20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jviromet.2004.12.003","article-title":"A novel rapid fluorescent focus inhibition test for rabies virus using a recombinant rabies virus visualizing a green fluorescent protein","volume":"125","author":"Khawplod","year":"2005","journal-title":"J Virol Methods"},{"key":"R21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3201\/eid1301.060810","article-title":"Rabies encephalitis in malaria-endemic area, Malawi, Africa","volume":"13","author":"Mallewa","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"R22","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/hmg\/10.19.2109","article-title":"Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery","volume":"10","author":"Mazarakis","year":"2001","journal-title":"Hum Mol Genet"},{"key":"R23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jneumeth.2006.04.011","article-title":"Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins","volume":"157","author":"Mentis","year":"2006","journal-title":"J Neurosci Methods"},{"key":"R24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"R25","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/JVI.78.6.2994-3002.2004","article-title":"Characterization of functional hepatitis C virus envelope glycoproteins","volume":"78","author":"Op De Beeck","year":"2004","journal-title":"J Virol"},{"key":"R26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1999.0633","article-title":"Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line","volume":"258","author":"Soda","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R27","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/2031355a0","article-title":"Syrian hamster fibroblast cell line BHK21 and its derivatives","volume":"203","author":"Stoker","year":"1964","journal-title":"Nature"},{"key":"R28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/carcin\/10.5.899","article-title":"Characterization of the human cell line TE671","volume":"10","author":"Stratton","year":"1989","journal-title":"Carcinogenesis"},{"key":"R29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/379085a0","article-title":"Sensitization of cells and retroviruses to human serum by (alpha 1\u20133) galactosyltransferase","volume":"379","author":"Takeuchi","year":"1996","journal-title":"Nature"},{"key":"R30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid1103.040906","article-title":"Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes","volume":"11","author":"Temperton","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1750-2659.2007.00016.x","article-title":"A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies","volume":"1","author":"Temperton","year":"2007","journal-title":"Influenza Resp Viruses"},{"key":"R32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1742-4690-4-40","article-title":"The control of viral infection by tripartite motif proteins and cyclophilin A","volume":"4","author":"Towers","year":"2007","journal-title":"Retrovirology"},{"key":"R33","doi-asserted-by":"crossref","first-page":"12295","DOI":"10.1073\/pnas.200286297","article-title":"A conserved mechanism of retrovirus restriction in mammals","volume":"97","author":"Towers","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"99","key":"R34","article-title":"Rabies","volume":"No","year":"2006","journal-title":"Fact Sheet"},{"key":"R35","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.72.4.3155-3160.1998","article-title":"Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines","volume":"72","author":"Wool-Lewis","year":"1998","journal-title":"J Virol"},{"key":"R36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat Biotechnol"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.2008\/000349-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T12:28:52Z","timestamp":1604492932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.2008\/000349-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,1]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9,1]]}},"URL":"https:\/\/doi.org\/10.1099\/vir.0.2008\/000349-0","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,1]]}}}